These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2659943)

  • 1. Bayes' Theorem for predicting human carcinogenicity.
    Ennever FK; Rosenkranz HS
    Mutagenesis; 1989 May; 4(3):241-3. PubMed ID: 2659943
    [No Abstract]   [Full Text] [Related]  

  • 2. The OSIRIS Weight of Evidence approach: ITS mutagenicity and ITS carcinogenicity.
    Buist H; Aldenberg T; Batke M; Escher S; Klein Entink R; Kühne R; Marquart H; Pauné E; Rorije E; Schüürmann G; Kroese D
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):170-81. PubMed ID: 23357514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are short-term genetic tests useful for predicting carcinogenicity? A panel discussion revisited.
    Gentile JM; Ashby J
    Environ Mol Mutagen; 1990; 16(4):324-7. PubMed ID: 2253609
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel naïve Bayes classification models for predicting the carcinogenicity of chemicals.
    Zhang H; Cao ZX; Li M; Li YZ; Peng C
    Food Chem Toxicol; 2016 Nov; 97():141-149. PubMed ID: 27597133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term tests for defining mutagenic carcinogens.
    Waters MD; Stack HF; Jackson MA
    IARC Sci Publ; 1999; (146):499-536. PubMed ID: 10353401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the carcinogenicity of a second group of organic chemicals undergoing carcinogenicity testing.
    Zhang YP; Sussman N; Macina OT; Rosenkranz HS; Klopman G
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):1045-50. PubMed ID: 8933053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in the application of Bayes' Theorem to child abuse decision making.
    Proeve M
    Child Maltreat; 2009 Feb; 14(1):114-20. PubMed ID: 18495947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating batteries of short-term genotoxicity tests.
    Ennever FK; Rosenkranz HS
    Mutagenesis; 1986 Jul; 1(4):293-8. PubMed ID: 3331669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The mutagenic and carcinogenic activity of chemical compounds].
    Rakitskiĭ VN; Turusov VS
    Vestn Ross Akad Med Nauk; 2005; (3):7-9. PubMed ID: 15852703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mammalian cell mutation assays in mutagenicity and carcinogenicity testing.
    Arlett CF; Cole J
    Mutagenesis; 1988 Nov; 3(6):455-8. PubMed ID: 3070282
    [No Abstract]   [Full Text] [Related]  

  • 11. Enter the reverend: introduction to and application of Bayes' theorem in clinical ophthalmology.
    Thomas R; Mengersen K; Parikh RS; Walland MJ; Muliyil J
    Clin Exp Ophthalmol; 2011 Dec; 39(9):865-70. PubMed ID: 21575118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of mammalian cell mutation assays in mutagenicity and carcinogenicity testing: reply to C.F. Arlett and J. Cole.
    Bolcsfoldi G
    Mutagenesis; 1989 Jul; 4(4):325. PubMed ID: 2674609
    [No Abstract]   [Full Text] [Related]  

  • 13. Guidelines for the testing of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
    Rep Health Soc Subj (Lond); 1982; 25():1-30. PubMed ID: 6765817
    [No Abstract]   [Full Text] [Related]  

  • 14. (Q)SAR Methods for Predicting Genotoxicity and Carcinogenicity: Scientific Rationale and Regulatory Frameworks.
    Bossa C; Benigni R; Tcheremenskaia O; Battistelli CL
    Methods Mol Biol; 2018; 1800():447-473. PubMed ID: 29934905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4.3 In-vitro genotoxicity tests to detect carcinogenicity: a systematic review.
    Müller L
    Hum Exp Toxicol; 2009 Feb; 28(2-3):131-3. PubMed ID: 19713378
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic toxicity and carcinogenicity studies of Kathon.
    Longacre SL; Wooder MF
    Environ Mol Mutagen; 1997; 29(3):331-3. PubMed ID: 9142178
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro carcinogenicity testing: present and future perspectives in pharmaceutical development.
    Kowalski LA
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):29-35. PubMed ID: 11727320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated approach to testing and assessment for predicting rodent genotoxic carcinogenicity.
    Petkov PI; Schultz TW; Donner EM; Honma M; Morita T; Hamada S; Wakata A; Mishima M; Maniwa J; Todorov M; Kaloyanova E; Kotov S; Mekenyan OG
    J Appl Toxicol; 2016 Dec; 36(12):1536-1550. PubMed ID: 27225589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A feasibility study: Can information collected to classify for mutagenicity be informative in predicting carcinogenicity?
    Petkov PI; Patlewicz G; Schultz TW; Honma M; Todorov M; Kotov S; Dimitrov SD; Donner EM; Mekenyan OG
    Regul Toxicol Pharmacol; 2015 Jun; 72(1):17-25. PubMed ID: 25792138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.